A new Utah law is expanding the definition of “specialized products”, and the implications could extend well beyond cannabinoids and nicotine.

In this episode of the Orange Pill Podcast, we unpack H.B. 385, the legislation introducing new licensing, testing, and reporting requirements for products with psychoactive, sedative, or analgesic properties.

From melatonin and botanicals to retailer liability and product transparency, we explore what this law could mean for the future of supplement regulation in the United States.